Home>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Tazobactam (CL-298741)

Tazobactam (CL-298741) (Synonyms: CL-298741, YTR 830H)

Catalog No.GC33927

Tazobactam (CL-298741) (CL-298741) is a potent β-lactamases inhibitor and penicillin antibiotic.

Products are for research use only. Not for human use. We do not sell to patients.

Tazobactam (CL-298741) Chemical Structure

Cas No.: 89786-04-9

Size Price Stock Qty
10mM (in 1mL DMSO)
$46.00
In stock
100mg
$37.00
In stock
200mg
$60.00
In stock
500mg
$101.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tazobactam is a beta Lactamase Inhibitor with antibacterial activityTarget: AntibacterialTazobactam is a pharmaceutical drug that inhibits the action of bacterial β-lactamases, especially those belonging to the SHV-1 and TEM groups. It is commonly used as its sodium salt, Tazobactam sodium.Tazobactam is combined with the extended spectrum β-lactam antibiotic piperacillin in the drug piperacillin/Tazobactam, one of the preferred antibiotic treatments for nosocomial pneumonia caused by Pseudomonas aeruginosa. Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that express β-lactamase and would normally degrade piperacillin. Tazobactam is derived from the penicillin nucleus and is a penicillinic acid sulfone.

Reviews

Review for Tazobactam (CL-298741)

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tazobactam (CL-298741)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.